COVID-19: Clinical Trials and Potential Therapeutic Agents - A Narrative Review
33 Pages Posted: 21 Jul 2020
Date Written: July 10, 2020
This review was undertaken to synthesize the data from various databases on ongoing and completed global clinical trials on potential therapeutic agents for the treatment of COVID-19 and, to find out the details and outcome of the completed trials as well as the rationale for selecting the trial drugs. Data on treatment trials registered during the period from January 2020 to July 5, 2020 and the therapeutic agents used were obtained from the databases on COVID-19, and the search engines, PubMed and Google Scholar. The search has shown that COVID-19 is found to be the only single disease with maximum registrations, 2710 trials. Therapeutic agents under testing include Hydroxychloroquine (HCQ), Remdesivir, Tocilizumab, Sarilumab, Lopinavir/Ritonavir, Glucocorticoids COVID-19 convalescent plasma, Mesenchymal stem cells, Interferons, Azithromycin, inhalational Nitric oxide and others. Among these, 131 trials were completed and the results are available for 8 trials. Out of these eight, two have shown favorable outcome for Favipiravir, one for HCQ alone, and one for HCQ + Azithromycin and one for Meplazumab. Top line data of two trials have resulted in the emergency use authorization (EUA) for Remdesivir on May 1, 2020. Identification of SARS-CoV2 protease Mpro and its inhibitors, namely, the two lead compounds 11 a and 11 b are the SARS-CoV2 specific drugs in COVID-19 new drug discovery and these protease inhibitors may probably emerge as promising anti-COVID drugs.
Note: Funding: None.
Conflict of interest: The authors declare that they have no conflict of interest.
Keywords: COVID-19, SARS-COV2, Clinical trials, Pharmacotherapy
Suggested Citation: Suggested Citation